Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Double-Dose Icotinib in EGFR L858R-Mutated Advanced Non-Squamous NSCLC
NCT05263947Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and icotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 18 months. Started Jan 2022; status: completed.
02
Drugs
bevacizumabicotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05263947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263947.